MOLOGEN receives Grant for Cell-based Cancer Therapy
The subsidies were granted for final pre-clinical development, to enable start of a clinical trial. MOLOGEN will start working on this project immediately. Subsequently, a phase I/II clinical trial can be initiated, where the therapeutic cell-based vaccine will be evaluated in patients with renal cell carcinoma. (RCC).
The innovations developed by MOLOGEN cover the cell-based, tumor-specific medicine as well as the necessary production procedures. Both of the MOLOGEN proprietary technologies will be employed in the medicine: MIDGE vectors to modify cells by special gene packages and dSLIM immunomodulators for stimulation and control of the patients immune response.
The tumor-specific therapy is expected to enable the body's own immune system of cancer patients to detect and destroy tumor cells. This is accomplished by application of 4-fold gene-modified and immunomodulated allogeneic tumor cells, which send recognition and activation signals from their cell surface. Allogeneic tumor cells (others than autologous tumor cells, used in related treatment regimes) are not the respective patient's own cells. They are produced instead for all patients from a previously accurately characterized and examined cell line.
MOLOGEN has a long standing and broad expertise in therapeutic anti-cancer vaccines and can use highly developed in-house infrastructures for development and production. They already finished a clinical trial, where gene-modified and immunomodulated, autologous tumor cells were successfully tested in RCC patients. MOLOGEN expects key-advantages, medically and commercially, compared to treatments with autologous cells. A successful "proof-of-concept" allogeneic approach with RCC patients, will open the door, to use gene-modified and immunomodulated cells for treatment of other, more frequent cancers than RCC. Future financing of advanced clinical trials is intended to be gained through MOLOGEN's Arabian business partners.
Meistgelesene News
Organisationen
Weitere News aus dem Ressort Wissenschaft
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Biotechnologie, Pharma und Life Sciences bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.